SCHEMBL13060673

SCHEMBL13060673

CCc1ccccc1CN(CCN(C)C)Cc1cccc(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.50
CAMKK2 Q96RR4 1/20 0.50
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.44
TSHR P16473 2/20 0.44
SLC1A5 Q15758 1/20 0.43
CYP2D6 P10635 4/20 0.42
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 2/20 0.42
RECQL P46063 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
MAPK1 P28482 2/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10039143 0.86 CALM1 (0.64) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13005546 0.85 CALM1 (0.47) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13061100 0.84 CALM1 (0.55) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13061135 0.82 CALM1 (0.44) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13060704 0.82 CALM1 (0.49) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13061136 0.78 CALM1 (0.48) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13060693 0.78 CALM1 (0.48) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13060700 0.78 CALM1 (0.65) CALM1CAMKK2ALDH1A1KDM4ETSHR
SCHEMBL13060690 0.77 CALM1 (0.40) CALM1CAMKK2ALDH1A1KDM4ELMNA
SCHEMBL13061102 0.77 CALM1 (0.64) CALM1CAMKK2ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed